Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Eur J Cardiothorac Surg. 2017 Sep 1;52(3):543-551. doi: 10.1093/ejcts/ezx132.
The purpose of this study was to determine the optimal timing of surgical resection of oesophageal adenocarcinoma following neoadjuvant chemoradiotherapy (nCRT).
nCRT before resection of oesophageal adenocarcinoma yields improved overall and progression-free survival. Despite the wide acceptance of tri-modal therapy, the optimal timing of surgical resection after nCRT is not well defined and existing studies are limited. Adults with Stage II/III oesophageal adenocarcinoma undergoing nCRT before surgery were identified from the National Cancer Database. Multivariable analysis using restricted cubic splines was used to identify an inflection point in clinical outcomes as a function of time between nCRT and surgery, dividing the cohort into short- and long-interval treatment groups, which were then compared. Adjusted rates of survival and margin status were compared between groups using multivariable analysis.
Among 2444 patients, restricted cubic splines identified an inflection point at 56 days, dividing our cohort into 1533 short-interval and 911 long-interval patients. Long-interval patients had a higher adjusted incidence of pathologic downstaging (odds ratio 1.38, confidence interval 1.02-1.85, P = 0.04) but no difference in margin positivity compared with short-interval patients (odds ratio 0.91, confidence interval 0.56-1.47, P = 0.69). Worse overall survival was noted in the long-interval subgroup (hazard ratio 1.44, confidence interval 1.22-1.71, P < 0.001), but 30-day postoperative mortality was not statistically different (odds ratio 1.56, confidence interval 0.9-2.72, P = 0.12).
Restricted cubic splines provides an objective mechanism to more accurately delineate optimum timing between nCRT and surgical resection. A time interval of 56 days represents an interval where increased pathologic downstaging is balanced by decreased overall survival.
本研究旨在确定新辅助放化疗(nCRT)后食管腺癌手术切除的最佳时机。
在切除食管腺癌之前进行 nCRT 可提高总生存率和无进展生存率。尽管三模式治疗被广泛接受,但 nCRT 后手术切除的最佳时机尚未明确,现有研究也有限。本研究从国家癌症数据库中确定了接受 nCRT 术前治疗的 II/III 期食管腺癌成人患者。使用受限立方样条的多变量分析来确定 nCRT 与手术之间时间作为临床结果的函数的转折点,将队列分为短间隔和长间隔治疗组,然后进行比较。使用多变量分析比较组间生存率和切缘状态的调整率。
在 2444 名患者中,受限立方样条确定了 56 天的转折点,将我们的队列分为 1533 名短间隔和 911 名长间隔患者。长间隔组患者的病理降期发生率较高(优势比 1.38,置信区间 1.02-1.85,P=0.04),但与短间隔组患者相比,切缘阳性率无差异(优势比 0.91,置信区间 0.56-1.47,P=0.69)。长间隔亚组的总生存率较差(风险比 1.44,置信区间 1.22-1.71,P<0.001),但 30 天术后死亡率无统计学差异(优势比 1.56,置信区间 0.9-2.72,P=0.12)。
受限立方样条为更准确地划定 nCRT 与手术切除之间的最佳时机提供了客观机制。56 天的时间间隔代表了增加病理降期与降低总生存率之间的平衡。